MCOPPB

MCOPPB
Identifiers
	IUPAC name 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole;
CAS Number	1028969-49-4 ; trihydrochloride: 1108147-88-1 ;
PubChem CID	24800108;
ChemSpider	21378267;
UNII	8NMK0UG3HV; trihydrochloride: SIO8DBP4K7 ;
CompTox Dashboard (EPA)	DTXSID401018254 ;
Chemical and physical data
Formula	C26H40N4
Molar mass	408.634 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1(CCCCCCC1)N2CCC(CC2)N3C4=CC=CC=C4N=C3[C@@H]5CCCNC5;
	InChI InChI=1S/C26H40N4/c1-26(15-7-3-2-4-8-16-26)29-18-13-22(14-19-29)30-24-12-6-5-11-23(24)28-25(30)21-10-9-17-27-20-21/h5-6,11-12,21-22,27H,2-4,7-10,13-20H2,1H3/t21-/m1/s1; Key:CYYNMPPFEJPBJD-OAQYLSRUSA-N;

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

MCOPPB is a drug which acts as a potent and selective agonist for the nociceptin receptor, with a pKi of 10.07 and much weaker activity at other opioid receptors. It has only moderate affinity for the mu opioid receptor, weak affinity for the kappa opioid receptor and negligible binding at the delta opioid receptor. In animal studies, MCOPPB produces potent anxiolytic effects, with no inhibition of memory or motor function, and only slight sedative side effects which do not appear until much higher doses than the effective anxiolytic dose range.^[1]^[2]

References

^ Hirao A, Imai A, Sugie Y, Yamada Y, Hayashi S, Toide K (March 2008). "Pharmacological characterization of the newly synthesized nociceptin/orphanin FQ-receptor agonist 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole as an anxiolytic agent". Journal of Pharmacological Sciences. 106 (3): 361–8. doi:10.1254/jphs.fp0071742. PMID 18319566.
^ Hayashi S, Hirao A, Imai A, Nakamura H, Murata Y, Ohashi K, Nakata E (February 2009). "Novel non-peptide nociceptin/orphanin FQ receptor agonist, 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole: design, synthesis, and structure-activity relationship of oral receptor occupancy in the brain for orally potent antianxiety drug". Journal of Medicinal Chemistry. 52 (3): 610–25. doi:10.1021/jm7012979. PMID 19125610.

This article about an anxiolytic is a stub. You can help Wikipedia by expanding it.

[1] Hirao A, Imai A, Sugie Y, Yamada Y, Hayashi S, Toide K (March 2008). "Pharmacological characterization of the newly synthesized nociceptin/orphanin FQ-receptor agonist 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole as an anxiolytic agent". Journal of Pharmacological Sciences. 106 (3): 361–8. doi:10.1254/jphs.fp0071742. PMID 18319566.

[2] Hayashi S, Hirao A, Imai A, Nakamura H, Murata Y, Ohashi K, Nakata E (February 2009). "Novel non-peptide nociceptin/orphanin FQ receptor agonist, 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole: design, synthesis, and structure-activity relationship of oral receptor occupancy in the brain for orally potent antianxiety drug". Journal of Medicinal Chemistry. 52 (3): 610–25. doi:10.1021/jm7012979. PMID 19125610.

[1]